In the multivariable analysis, which adjusted for all covariates, the incidence of cervical cancer was significantly lower in the SGLT2 inhibitor group than in the control group (aHR, 0.77; 95% CI, 0.62-0.96, P = 0.0179; Tables 2 and 3). This evidence concerns the gene SLC5A2 and cervical carcinoma.